A 68-year-old man presented to the emergency department with haematuria and penile pain. His medical history included benign prostatic hyperplasia, but no follow-up examinations had been performed.

AI could eliminate the "postcode lottery" surrounding a life-extending treatment for advanced prostate cancer, researchers have said. A recent study found that AI can identify patients who will ...

The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...

Growing evidence indicates that more patients with favorable Grade Group 2 prostate cancer can be successfully managed with active surveillance and achieve acceptable oncologic outcomes, even if later ...

About 1 in 8 men will get prostate cancer in their lifetime. But a new study concludes an increasing number of men with limited life expectancy are being overtreated for the disease with procedures ...

Effective cancer screening protocols can dramatically alter outcomes for patients. Prostate cancer, for example, has been one of the most common cancers among men in the United States for decades. In ...

Prostate cancer patients could have a new treatment on the horizon. A new study published in the journal Nature has found that for some patients with treatment-resistant prostate cancer, a new process ...

Genetic testing, including germline and somatic, is vital for prostate cancer prognosis and personalized treatment strategies. PARP inhibitors, targeting BRCA mutations, are a promising therapy for ...

One test could have prevented terminal prostate cancer, says patient - Research has shown that the use of the PSA test varies ...

A newly expanded prostate cancer drug could bring new hope to patients with a common form of the disease. Novartis, a Switzerland-based pharmaceutical company, announced on March 28 that the U.S. Food ...